|
Impact of different antimycotics on cytokine levels in an in-vitro aspergillosis model in human whole blood (click for details) |
|
|
|
A prospective multi-center evaluation of circulating galactomannan, 1,3-β-D-glucan and Aspergillus DNA for detection of invasive aspergillosis in high-risk patients with haematological malignancies in Greece (click for details) |
|
|
|
Empiric piperacillin-tazobactam versus carbapenem in febrile neutropenia : increased incidence of invasive pulmonary aspergillosis (click for details) |
|
|
|
VITEK (R) MS in clinical and environmental Aspergillus spp. identification (click for details) |
|
|
|
Clinical outcomes in patients with chronic pulmonary aspergillosis following discontinuation of therapy (click for details) |
|
|
|
Invasive aspergillosis in renal transplant patients : a case control study (click for details) |
|
|
|
Modifications of triazole therapy and clinical outcomes in chronic pulmonary aspergillosis (click for details) |
|
|
|
Monitoring of invasive aspergillos is antifungal therapy by quantitative reverse transcriptase real-time polymerase chain reaction (qRT- PCR) (click for details) |
|
|
|
Chronic pulmonary aspergillosis in cystic fibrosis patients (click for details) |
|
|
|
Azole-resistant Aspergillus fumigatus at a university hospital in Belgium: a laboratorybased surveillance (click for details) |
|
|
